Boston Scientific Corporation
One Boston Scientific Place
1468 articles with Boston Scientific Corporation
Boston Scientific Initiates Trial Comparing Left Atrial Appendage Closure to Direct Oral Anticoagulants for Stroke Risk Reduction Post-AFib Ablation
Findings could expand number of patients who can receive alternative treatment to life-long use of blood thinners
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on Their Investment in Boston Scientific Corporation of Class Action Lawsuit and Upcoming Deadline - BSX
Pomerantz LLP announces that a class action lawsuit has been filed against Boston Scientific Corporation and certain of its officers.
Late-Breaking Trial Data Highlight Continued Clinical Success Of Boston Scientific EMBLEM™ S-ICD System
New data further support use of S-ICD System as first-line therapy for majority of ICD patients
Acquisition of lumbar spinal stenosis treatment to expand portfolio of interventional pain therapies
Boston Scientific (NYSE: BSX) has announced that it has entered into a definitive agreement to acquire Vertiflex, Inc., a privately-held company which has developed and commercialized the Superion® Indirect Decompression System,
Boston Scientific Corporation (NYSE: BSX) will participate in the 2019 UBS Global Healthcare Conference on Tuesday, May 21, 2019 in New York City.
New Stent System Now Available for Treating Patients with Deep Venous Blockages
Bank of America Merrill Lynch Healthcare Conference 2019 on Wednesday, May 15, 2019 in Las Vegas.
Boston Scientific Corporation announced key data that will be featured at Heart Rhythm 2019, the Heart Rhythm Society's 40th Annual Heart Rhythm Scientific Sessions, in San Francisco on May 8-11.
Thornton Law Firm LLP announces that it is investigating a securities class action on behalf of shareholders and investors who purchased the securities of Boston Scientific Corporation.
Johnson Fistel Announces Class Action Suit against Boston Scientific Corporation (BSX); Encourages Investors to Contact the Firm for Additional Information
Shareholder rights law firm Johnson Fistel, LLP reminds investors that a class action lawsuit has been filed against Boston Scientific Corporation on behalf of all purchasers of common stock during the period between February 26, 2015 through April 16, 2019, inclusive.
Boston Scientific Corporation generated sales of $2.493 billion during the first quarter of 2019.
Transcatheter Aortic Valve Replacement Technology for Patients with Severe Aortic Stenosis Designed to Minimize Paravalvular Leakage, Offer Controlled Delivery and Repositionability Post Deployment
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the first quarter ended March 31, 2019 on Wednesday, April 24, 2019 at 8:00 a.m. EDT.
Late-breaking Clinical Trial Highlights Positive Safety and Efficacy Data for the LUMINIZE™ RF Balloon Catheter
New data showcasing performance of recently acquired RF balloon-based, single-shot ablation technology
Boston Scientific Corporation announced key data that will be featured at EHRA 2019, the annual congress of the European Heart Rhythm Association in Lisbon, Portugal, on March 17-19.
VIVA Physicians Selects NAMSA as Statistical Analytic Group to Evaluate the Safety of Paclitaxel Drug-Eluting Technologies in PAD
VIVA Physicians announced the selection of NAMSA as the independent statistical analysis group to examine individual patient-level data associated with paclitaxel-coated balloons and stent trials used in the treatment of peripheral artery disease in the superficial femoral artery.
Boston Scientific Corporation will participate in the Cowen and Company 39th Annual Healthcare Conference on Wednesday, March 13, 2019 in Boston.
Boston Scientific Completes $4.3 Billion Offering of Senior Notes and Issues Redemption Notice for its 2020 Notes
Boston Scientific Corporation completed a public offering of $4.3 billion aggregate principal amount of its senior notes.
Boston Scientific Corporation announced the pricing of a public offering of $4.3 billion aggregate principal amount of its senior notes under the Company's shelf registration statement.